Ascletis announced that the new crown oral drug 3CLpro inhibitor ASC11 has submitted a clinical trial application for new drugs in the United States
Time of Update: 2022-11-15
Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") today announced that it has submitted an application for a new drug clinical trial (IND) for ASC11, an oral drug candidate, protease (3CLpro) inhibitor, following a pre-IND consultation.
East Sunshine Medicine has 33 Class 1 new drugs dominating the screen, and 42 varieties have been evaluated
Time of Update: 2022-11-04
Recently, East Sunshine Pharmaceutical's product line has been dynamic: Class 1 new drug HEC138671 tablets have been approved for clinical trials, insulin aspart injection has been approved for marketing, and the first generic patent challenge of fingolimod capsules has been successful.
New Oral Drug May Be Alternative to ESAs for Renal Anemia in Dialysis-Initiating Patients, New Study Shows
Time of Update: 2022-06-18
The study shows that the oral drug Daparodustat is safe and effective, non-inferior to ESAs, and can be used as another powerful tool for intervening renal anemia in patients with initial dialysis² .
Intervention Phase: Patients who successfully pass screening will be randomized 1:1 to Daparodustat and ESAs (darbepoetin alfa) .
"Safety Investigator" Sees Bloodborne vs. Restructuring FVIII Safety
Time of Update: 2022-06-14
The use of recombinant FVIII to replace blood-derived FVIII greatly reduces the risk of viral infection and greatly improves the safety of the treatment of hemophilia A patients 6 .
Received five FDA qualifications in one year
Time of Update: 2022-03-06
S. Food and Drug Administration (FDA) has granted its placental hematopoietic stem cell-derived natural killer (NK) Orphan drug designation for cell therapy CYNK-101 for the treatment of gastric or gastroesophageal junction (G/GEJ) cancers .
Combination of precision therapy for first-line treatment of leukemia significantly prolongs patient survival time
Time of Update: 2022-02-26
Daiichi Sankyo announced that the oral FLT3 inhibitor quizartinib, in combination with standard chemotherapy, met its primary endpoint in a Phase 3 clinical trial in the first-line treatment of patients with FLT3-ITD-mutated acute myeloid leukemia (AML).
The 2nd paragraph in the country
Time of Update: 2022-02-25
Article source: Medical Cube InfoOn November 29, Junshi Bio announced that the clinical trial application for Aurora A inhibitor WJ05129 tablets (JS112) of Suzhou Junjing Bio (which jointly invested with Weijing Bio) has been accepted by NMPA .
Dyne Pharmaceutical's Lycorine Hydrochloride Thioester for Injection Obtained Approval for Drug Clinical Trials
Time of Update: 2022-02-23
At present, the drugs for the treatment of hand, foot and mouth disease that other companies have declared in China and intend to continue to develop are mainly oral dosage forms .
Moderna plans to launch a three-in-one vaccine for COVID-19/flu/RSV
Time of Update: 2022-02-20
According to the latest news, Moderna is actively preparing to launch a three-in-one vaccine by fall 2023, which will be effective against both COVID-19 and influenza, and also prevent respiratory syncytial virus (RSV) infection .
Eli Lilly's "baricitinib" new indication was listed in domestic reports
Time of Update: 2022-01-25
In July 2019, the State Drug Administration approved the marketing of baricitinib tablets for the treatment of moderately to severely active rheumatoid arthritis in adults, with the trade name of elemin .
Stroke: a new quantitative score that can more effectively predict posterior circulation ischemia
Time of Update: 2022-01-22
, University of Melbourne, assessed the prognostic value of additional clinical features in conservatively treated patients with posterior circulation stroke and mild-to-moderate symptoms (NIHSS score <10), and used this information to derive and validate NIHSS A modified version, ie Post-NIHSS (POST-NIHSS) .
Severe protection rate of 96%, Cansino adenovirus vector new crown vaccine phase III clinical results announced
Time of Update: 2022-01-08
This international multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluated the effectiveness, safety, and immunogenicity of a single dose of Kevisa in adults 18 years and older .
5% effectiveness in preventing symptomatic COVID-19 disease 28 days after vaccination and 91.
Hutchison Medical's introduction of anti-tumor drug tazemetostat tablets for more than 300 million US dollars applies for clinical application in China
Time of Update: 2021-12-30
Screenshot source: CDE official websitePublic information shows that tazemetostat is a "first-in-class" EZH2 methyltransferase inhibitor developed by Epizyme.
In addition, tazemetostat is also being developed for the treatment of diffuse large B-cell lymphoma, prostate cancer and ovarian cancer .
Lancet Sub-Journal: Analysis of the efficacy of pimaserin in the treatment of schizophrenia
Time of Update: 2021-12-26
In order to evaluate the effect of pimaserin on the negative symptoms of schizophrenia, experts from Sweden conducted a study called ADVANCE-a 26-week randomized, double-blind, placebo-controlled phase 2 study.
1016/S2215-0366(21)00386-2Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
Lancet: To reduce the toxicity and increase the effect, what is the new treatment of "sling" cyclosporine
Time of Update: 2021-12-07
For medical professionals to read and refer to clinical information only, 1s voclosporin (voclosporin) is a new generation of calcineurin inhibitor (CNi), which can be used to prevent rejection after organ transplantation and treat autoimmunity Disease .